ReviewDrugs2013
Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.
Review in Drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03009422 (Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Interventions for Old World cutaneous leishmaniasis.The Cochrane database of systematic reviews · 2017Pooled it
- Interventions for Old World cutaneous leishmaniasis.The Cochrane database of systematic reviews · 2017Pooled it
- A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New World.PLoS neglected tropical diseases · 2022Trial
- Addressing the Gaps and Challenges of Autochthonous Mucocutaneous Leishmaniasis in Spain.Tropical medicine and infectious disease · 2026Review
- A case report: Cutaneous leishmaniasis mimicking leprosy in an immunocompetent young adult: A diagnostic and therapeutic challenge in the Old World.JAAD case reports · 2026Article
- Nanofibrous patches for targeted therapy of cutaneous leishmaniasis caused by Leishmania major: a preclinical amphotericin B platform.Parasitology research · 2025Article
- Cutaneous and Mucocutaneous Leishmaniasis: Perspectives on Immunity, Virulence, and Treatment.Biomedicines · 2025Review
- Investigation of Viscoelastic Properties of Macrophage Membrane-Cytoskeleton Induced by Gold Nanorods in Leishmania Infection.Nanomaterials (Basel, Switzerland) · 2025Article
- Recent advances in the genetic engineering of theIranian journal of basic medical sciences · 2025Review
- In vitro evaluation of antileishmanial activity of Boswellia serrata essential oil nanoliposome.Veterinary medicine and science · 2024Article
- Article
- Involving patients in drug development for Neglected Tropical Diseases (NTDs): A qualitative study exploring and incorporating preferences of patients with cutaneous leishmaniasis into Target Product Profile development.PLoS neglected tropical diseases · 2024Article
- Impetiginous Cutaneous Leishmaniasis after COVID-19 Infection in a Patient with Poor Cardiac Profile: A Case Report and Literature Review.Tropical medicine and infectious disease · 2023Article
- Macrophage metallothioneins participate in the antileishmanial activity of antimonials.Frontiers in parasitology · 2023Article
- Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions.Parasites & vectors · 2022Article
- Establish an allele-specific real-time PCR for Leishmania species identification.Infectious diseases of poverty · 2022Article
- Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review.Infectious diseases and therapy · 2022Review
- Domestic mammals as reservoirs for Leishmania donovani on the Indian subcontinent: Possibility and consequences on elimination.Transboundary and emerging diseases · 2022Review
- Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.Pathogens (Basel, Switzerland) · 2021Article
- Using Q-methodology to understand the perspectives and practical experiences of dermatologists about treatment difficulties of cutaneous leishmaniasis.BMC infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Estimated worldwide incidence of tegumentary leishmaniasis (cutaneous leishmaniasis [CL] and mucocutaneous leishmaniasis [MCL]) is over 1.5 million cases per year in 82 countries, with 90 % of cases occurring in Afghanistan, Brazil, Iran, Peru, Saudi Arabia and Syria. Current treatments of CL are poorly justified and have sub-optimal effectiveness. Treatment can be based on topical or systemic regimens. These different options must be based on Leishmania species, geographic regions, and clinical presentations. In certain cases of Old World CL (OWCL), lesions can spontaneously heal without any need for therapeutic intervention. Local therapies (thermotherapy, cryotherapy, paromomycin ointment, local infiltration with antimonials) are good options with less systemic toxicity, reserving systemic treatments (azole drugs, miltefosine, antimonials, amphotericin B formulations) mainly for complex cases. The majority of New World CL (NWCL) types require systemic treatment (mainly with pentavalent antimonials), either to speed the healing or to prevent dissemination to oral-nasal mucosa as MCL (NWMCL). These types of lesions are potentially serious and always require systemic-based regimens, mainly antimonials and pentamidine; however, the associated immunotherapy is promising. This paper is an exhaustive review of the published literature on the treatment of OWCL, NWCL and NWMCL, and provides treatment recommendations stratified according to their level of evidence regarding the species of Leishmania implicated and the geographical location of the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.